Ticker brief

ZYME

last close
·
1 day
·
14 days
·
mkt cap
·
signals 14d
10
authors 14d
9

No price history on file for this name (likely non-equity or unlisted) — the “since then” column below stays blank.

Sentiment — last 14 days
daily mean sentiment, 2026-06-29 → 2026-06-30 · now +0.20 (−1 bearish … +1 bullish)
Who spoke9
authorgradetrader scoresignalsmean sent
@PersimmonTIA-0.322+0.08
@semodoughC-0.751-0.10
@BioStocksC-0.391-0.10
@MartyCharginC-0.721-0.10
@fwpharmaB+0.221-0.10
@OpenOutcrierC·1-0.10
@BiopharmIQB·1-0.10
@BenzingaC-2.471+0.20
@Brad_E_SchulzC·1+0.20
Recent signals10of 10 in 14d — receipts included
date (PT)authorsentwhat they saidsince thenreceipt
2026-06-30@Brad_E_Schulz+0.20Midday sector performance overview with bio/pharm and other categories plus percent gainers.·
2026-06-29@Benzinga+0.20Zymeworks targets long-term cash generation through Theravance acquisition.·
2026-06-29@BiopharmIQ-0.10ZYME to acquire TBPH in $17/share all-cash deal valued near $929M plus CVR.·
2026-06-29@OpenOutcrier-0.10Theravance Biopharma to be acquired by Zymeworks for $17 per share plus CVR.·
2026-06-29@fwpharma-0.10Zymeworks buying Theravance for $929M.·
2026-06-29@PersimmonTI+0.20Says list of non-traditional XBI acquirers continues to grow, a good sign.·
2026-06-29@PersimmonTI-0.05Comments on TBPH x ZYME as a take-under with CVR.·
2026-06-29@MartyChargin-0.10Theravance agreed to be acquired by Zymeworks for $17 per share in cash.·
2026-06-29@BioStocks-0.10ZYME to acquire TBPH for $17 per share.·
2026-06-29@semodough-0.10Zymeworks to acquire Theravance Biopharma.·

“Since then” = price move from the close on the signal's date (PT) to the latest close — what happened after they said it, not a backtest. A — means no trading session has closed since the signal yet. Sentiment is our extracted per-tweet score, −1…+1.